These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 24636474)

  • 1. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).
    Syed A; Garcia MA; Lyu SC; Bucayu R; Kohli A; Ishida S; Berglund JP; Tsai M; Maecker H; O'Riordan G; Galli SJ; Nadeau KC
    J Allergy Clin Immunol; 2014 Feb; 133(2):500-10. PubMed ID: 24636474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and analysis of peanut-specific effector T and regulatory T cells in children allergic and tolerant to peanut.
    Weissler KA; Rasooly M; DiMaggio T; Bolan H; Cantave D; Martino D; Neeland MR; Tang MLK; Dang TD; Allen KJ; Frischmeyer-Guerrerio PA
    J Allergy Clin Immunol; 2018 May; 141(5):1699-1710.e7. PubMed ID: 29454004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and immune regulation with peanut oral immunotherapy.
    Jones SM; Pons L; Roberts JL; Scurlock AM; Perry TT; Kulis M; Shreffler WG; Steele P; Henry KA; Adair M; Francis JM; Durham S; Vickery BP; Zhong X; Burks AW
    J Allergy Clin Immunol; 2009 Aug; 124(2):292-300, 300.e1-97. PubMed ID: 19577283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.
    Varshney P; Jones SM; Scurlock AM; Perry TT; Kemper A; Steele P; Hiegel A; Kamilaris J; Carlisle S; Yue X; Kulis M; Pons L; Vickery B; Burks AW
    J Allergy Clin Immunol; 2011 Mar; 127(3):654-60. PubMed ID: 21377034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
    Vickery BP; Scurlock AM; Kulis M; Steele PH; Kamilaris J; Berglund JP; Burk C; Hiegel A; Carlisle S; Christie L; Perry TT; Pesek RD; Sheikh S; Virkud Y; Smith PB; Shamji MH; Durham SR; Jones SM; Burks AW
    J Allergy Clin Immunol; 2014 Feb; 133(2):468-75. PubMed ID: 24361082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
    Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
    Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
    Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current opinion and review on peanut oral immunotherapy.
    Deol S; Bird JA
    Hum Vaccin Immunother; 2014; 10(10):3017-21. PubMed ID: 25483680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Milk Oral Immunotherapy Promotes Generation of Casein-Specific CD137
    Zhang Y; Li L; Genest G; Zhao W; Ke D; Bartolucci S; Pavey N; Al-Aubodah TA; Lejtenyi D; Torabi B; Ben-Shoshan M; Mazer B; Piccirillo CA
    Front Immunol; 2021; 12():705615. PubMed ID: 34887847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of the immunologic response to peanut during immunotherapy is often transient.
    Gorelik M; Narisety SD; Guerrerio AL; Chichester KL; Keet CA; Bieneman AP; Hamilton RG; Wood RA; Schroeder JT; Frischmeyer-Guerrerio PA
    J Allergy Clin Immunol; 2015 May; 135(5):1283-92. PubMed ID: 25542883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate and adaptive dendritic cell responses to immunotherapy.
    Gorelik M; Frischmeyer-Guerrerio PA
    Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):575-80. PubMed ID: 26509662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergen-specific oral immunotherapy for peanut allergy.
    Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009014. PubMed ID: 22972130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forkhead box protein 3 demethylation is associated with tolerance induction in peanut-induced intestinal allergy.
    Wang M; Yang IV; Davidson EJ; Joetham A; Takeda K; O'Connor BP; Gelfand EW
    J Allergy Clin Immunol; 2018 Feb; 141(2):659-670.e2. PubMed ID: 28479331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired.
    Pellerin L; Jenks JA; Chinthrajah S; Dominguez T; Block W; Zhou X; Noshirvan A; Gregori S; Roncarolo MG; Nadeau KC; Bacchetta R
    J Allergy Clin Immunol; 2018 Jan; 141(1):202-213.e8. PubMed ID: 28689791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Food-allergic infants have impaired regulatory T-cell responses following in vivo allergen exposure.
    Dang TD; Allen KJ; J Martino D; Koplin JJ; Licciardi PV; Tang ML
    Pediatr Allergy Immunol; 2016 Feb; 27(1):35-43. PubMed ID: 26456457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
    Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA
    J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
    Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
    J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
    Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
    Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
    J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
    Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.